{"Q": 1, "answer": "no", "rationale": "The comparative 'better' modifies the verb 'match', not a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_16388", "batch_size": 260, "batch_pos": 161, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment describes company actions and purpose factually, without high-potency framing.", "method": "llm_batch", "batch_id": "batch_2_13772", "batch_size": 260, "batch_pos": 126, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment is about vaccine development and testing, not virus impact.", "method": "llm_batch", "batch_id": "batch_3_6040", "batch_size": 260, "batch_pos": 60, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "Segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_14784", "batch_size": 260, "batch_pos": 36, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports on vaccine development as a precautionary measure, which falls under Q7 (Capability) not Q5 (Explicit Calming).", "method": "llm_batch", "batch_id": "batch_5_15088", "batch_size": 260, "batch_pos": 34, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser used in conjunction with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_13440", "batch_size": 260, "batch_pos": 258, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment states executives told Reuters they are developing/testing vaccines, not a bare negation.", "method": "llm_batch", "batch_id": "batch_7_9220", "batch_size": 260, "batch_pos": 238, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "regex:CapabilityNoReassurance matched", "method": "regex", "batch_id": "batch_8_17656", "batch_size": 260, "batch_pos": 94, "regex": {"rule": "CapabilityNoReassurance", "span": [20, 27], "captures": []}, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
